A research using three cisplatin-relapsing ovarian cancer PDX models based on the presence of activation of the RAS/RAF/MEK/ERK axis and PI3K pathway, p53 mutation and lack of phosphatase and tensin homolog (PTEN) expression, confirmed that triple combination of bevacizumab, MEK162 (a MEK inhibitor) and paclitaxel displayed a more effective antitumor activity than any double drug combination for relapsing ovarian tumors in second line treatment 69. The gene discussed is PTEN; the disease is ovarian cancer.